XomeXBio

Active

Private limited companyfounded 2023active for 3 yearsRue Clément Ader 10, 6041 Charleroi, Belgium36 active companies are registered at this addressKBO/BCE: BE 0801.880.687

Summary

The annual accounts of XomeXBio for financial year 2025 show a net loss of 781% of the equity at the start of that year. The 2025 annual accounts show equity of €1.1m and a net result of -€528,922. Equity is growing by about 514% per year across the filed financial years. Its solvency ranks better than 40% of 271 sector peers (NACE 72, financial year 2025). The company has been active since 2023 and the Belgian Official Gazette contains no insolvency or warning signals. The computed 12-month bankruptcy probability is 0.7% (low).

Risk analysisFollow Report Compare

XomeXBioActiveChecked score 55/100

Risk analysis Report Compare

Activity

Research and development on biotechnology

NACE 72101

1 site

Size

€3.5mtotal assets 2025

Staff: 4 FTE
Equity: €1.1m
Loss: -€528,922

Financial health

55 Fair Checked score 2025

Bankruptcy probabilitywithin 12 months: 0.7%

Structure

Board: 4 members

JPP CONSULTING SRLChair · permanent representative Jean-Paul Prieels
TONGLET CONSULT SRLManaging director · permanent representative Frédéric Tonglet

2025 accounts 16 days early3 of 4 deeds summarised

Why 55raises riskCapped at 59: a net loss of at least half of total assets or of the equity at the start of the financial yearLoss of €528,922, the second in a row (financial year 2025)lowers riskSector: Scientific research and development (NACE 72)Figures for financial year 2025 (filed 15-07-2026)Size: 4 FTE, total assets €3.5mShow the evidence

Checked score

Score 2025

55 / 100

Fair

Probability in this band: 1.5% to 4.2%

Financially better than 45% of its sector peers (NACE 72, micro)

A net loss of at least half of total assets or of the equity at the start of the financial year caps the score at 59. Every signal that counts is listed under Signals.

Financial strength · tick = 2024

Weak

Solvency 55+26

equity 30.2% of total assets

Liquidity 53+13

short-term debt 6.4% · cash 2.3%

Profitability 0=

return on assets -15.1%

Bankruptcy probability, 12 months

0.7% Low

0%0.5%1.5%4%10%≥ 25%

About 7 in 1,000 comparable companies go bankrupt within 12 months (an estimate).

Sector median 0.1% (935 companies, NACE 72, micro)

Last 24 months 11-2024: 0.2% 12-2024: 0.2%● unchanged vs 11-2024 01-2025: 0.2%● unchanged vs 12-2024lowest value 02-2025: 0.2%● unchanged vs 01-2025lowest value 03-2025: 0.2%● unchanged vs 02-2025 04-2025: 0.2%● unchanged vs 03-2025 05-2025: 0.2%● unchanged vs 04-2025 06-2025: 0.3%▲ +0.1 percentage points vs 05-2025 07-2025: 0.3%● unchanged vs 06-2025 08-2025: 0.6%▲ +0.3 percentage points vs 07-2025 09-2025: 0.8%▲ +0.2 percentage points vs 08-2025 10-2025: 2.6%▲ +1.8 percentage points vs 09-2025highest value 11-2025: 2.6%● unchanged vs 10-2025highest value 12-2025: 2.6%● unchanged vs 11-2025highest value 01-2026: 2.6%● unchanged vs 12-2025 02-2026: 2.6%● unchanged vs 01-2026 03-2026: 2.5%▼ -0.1 percentage points vs 02-2026 04-2026: 2.6%▲ +0.1 percentage points vs 03-2026 05-2026: 1.6%▼ -1.0 percentage point vs 04-2026 06-2026: 1.6%● unchanged vs 05-2026 07-2026: 1.7%▲ +0.1 percentage points vs 06-2026 08-2026: 0.8%▼ -0.9 percentage points vs 07-2026 09-2026: 0.8%● unchanged vs 08-2026 10-2026: 0.7%▼ -0.1 percentage points vs 09-2026

Credit of up to €55,000 on 30-day terms, only on tighter conditions

Net loss of at least half of total assets or of the equity at the start of the financial year.

Liquidity ample (current ratio 5.93, compared with 1.14 in 2024, above the usual 1.5; short-term debt: 6.4% and cash: 2.3% of total assets), but 69.8% of the assets are financed with debt and provisions.

How it is calculated

The band follows from the bankruptcy probability, on a scale where 10 more points roughly halve it:

75-100	Excellent	under 0.55%
60-74	Healthy	0.55% to 1.5%
45-59	Fair	1.5% to 4.2%
25-44	Weak	4.2% to 15.0%
0-24	Critical	over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 72, micro): better than 33% on solvency, 38% on liquidity, 10% on profitability and 99% on growth.

The bankruptcy probability was computed on 24-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

Some facts cap the score, however low the probability. Negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late hold it at Fair at most (59); two missing filings, at Weak (44). An ongoing judicial reorganisation or the company's end (bankruptcy, dissolution, liquidation) holds it at Critical at most (24).

Credit check for your own amount and term

Show the recommended maximum and see how the verdict changes with amount, term and advance.

Signals

Five signals.

lowers riskraises riskneutral

Sector: Scientific research and development (NACE 72)

KBO

Loss of €528,922, the second in a row (financial year 2025)

NBB · annual accounts

Figures for financial year 2025 (filed 15-07-2026)

NBB · annual accounts

Size: 4 FTE, total assets €3.5m

Companies of this size fail less often; how much that weighs depends on the rest of its profile.

NBB · annual accounts

Latest accounts filed on time

The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 15-07-2026, 16 days ahead of the deadline.

NBB · 3 filings

Deviation from the deadline

2025

16 days early

2024

35 days late

2023

30 days late

← before the deadline after the deadline →

tick = median of all Belgian filingsring = median in the sector

This company filed its last 3 accounts on average 16 days after the deadline; the sector median (NACE 72) for financial year 2024 is 13 days before the deadline, and 32% of those companies filed late.

Searched, nothing found (2)

Next filing not due yet

The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 31 August (3 of the last 3 filed years within 47 days of that day).

Companies Code · seven months

Where today falls in the filing period

25-10-2026 today31-12-2026 year end31-07-2027 deadline

No strike-offs in the KBO publications

Searched since incorporation in 2023.

KBO publications · our coverage

15-07-2026 Annual accounts filedfinancial year 2025 · abbreviated…
31-12-2025 Liquidity more than 5 timescurrent ratio 5.93
31-12-2025 Equity above €1mequity €1.1m ▲1,460%

Key points

Risk: 3 loss-making years in a rowloss financial year 2025 -€528,922 View
Positive: Equity rose in 2025from €67,716 to €1.1m ▲ 16× View
Caution: Among the weakest 16% on net resultsector median €1,640 · 270 companies -€528,922 View

By topic

Financials

Financial year: 2025
Total assets: €3.5m
Loss: -€528,922
Solvency: 30.2%

Total assets▲ 130%

Net result

20232025

Go to Financials

Board & ownership

Board: 4 members

JPP CONSULTING SRLChair
Hui YangDirector
SiHui ChenDirector
TONGLET CONSULT SRLManaging director

Go to Board & ownership

Network & group

Connected companies: 1

Go to Network & group

Timeline

Events: 9
Since: 2024
Next accounts: by 31-07-2027

22-12-2025Capital & shares · Amendment of the…
04-09-2025Annual accounts filed
31-12-2024Weakest financial year

Go to Timeline

Company details

Sites: 1

Legal form: Private limited company
Activity: Research and development on biotechnologyNACE 72101
Founded: 17-05-2023
Year ends: 31-12
Peppol: Reachable for e-invoices

Go to Company details

Key facts about XomeXBio

What is the company number of XomeXBio?: 0801.880.687. In Belgium the VAT number is the company number with BE in front: BE 0801.880.687.
Where is XomeXBio based?: The registered office is at Rue Clément Ader 10, 6041 Charleroi.Company details
What does XomeXBio do?: According to the KBO register, the main activity is research and development on biotechnology (NACE 72101).
What is the legal form of XomeXBio?: Private limited company (BV).
When was XomeXBio founded?: On 17-05-2023.
Is XomeXBio still active?: Yes, XomeXBio is an active enterprise in the KBO register.
How many employees does XomeXBio have?: On average 4 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
What is the turnover of XomeXBio?: Not stated in the processed annual accounts. The abridged format for small companies does not require turnover.
Is XomeXBio profitable?: In financial year 2025, XomeXBio made a loss of €528,922.
Where can I find the annual accounts of XomeXBio?: XomeXBio filed 3 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of XomeXBio due?: By 31-07-2027, for financial year 2026.Timeline